» Articles » PMID: 29235126

Relationships of Serum 25-hydroxyvitamin D, Ionized Calcium and Parathyroid Hormone After Obesity Surgery

Overview
Specialty Endocrinology
Date 2017 Dec 14
PMID 29235126
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The high prevalence of secondary hyperparathyroidism (SHPT) after obesity surgery is a concern for long-term bone health. Limited knowledge exists about optimal vitamin D and suppression of parathyroid hormone (PTH) after these procedures. The aim of this study was to investigate the prevalence of SHPT and its relation to vitamin D status.

Design: A cross-sectional study at Oslo University Hospital, Norway.

Patients: A total of 502 consecutive patients, age 22-64 years, attending 2-year follow-up after Roux-en-Y gastric bypass.

Measurements: A serum intact PTH >7.0 pmol/L in the absence of elevated serum ionized calcium (iCa) was considered as SHPT. Vitamin D status was defined by serum concentrations of 25-hydroxyvitamin D (S-25(OH)D).

Results: Altogether, 171 patients (34%) had SHPT. The prevalence of SHPT varied across the range of S-25(OH)D (P < 0.001), being highest (71%) with S-25(OH)D < 25 nmol/L. Compared with S-25(OH)D < 50 nmol/L, the prevalence of SHPT was lower with S-25(OH)D ≥ 50 nmol/L (29.0%; RR = 0.64 (95%-CI:0.50-0.81)) and S-25(OH)D ≥ 75 nmol/L (27.7%; RR = 0.61 (95%-CI:0.44-0.84)). S-25(OH)D ≥ 100 nmol/L was associated with the lowest PTH and the lowest prevalence of SHPT (16.0%; RR = 0.35 (95%-CI:0.14-0.88) compared with S-25(OH)D < 50 nmol/L) and the most normal calcium distribution. These associations were most pronounced with iCa in the lower range. A synergistic association was found for S-25(OH)D and iCa on SHPT.

Conclusions: Vitamin D deficient patients had the highest prevalence of SHPT 2 years after gastric bypass. PTH and the prevalence of SHPT were notably lower with S-25(OH)D ≥ 100 nmol/L, compared with lower target levels.

Citing Articles

A Nomogram for Predicting Secondary Hyperparathyroidism after Bariatric Surgery: A Retrospective Study on Short-Term Outcome.

Wang P, Zhang Y, Liu B, Nie Y, Zhou H, Meng H Obes Surg. 2024; 35(1):206-215.

PMID: 39707145 DOI: 10.1007/s11695-024-07623-5.


Changes in bone turnover markers 6-12 months after bariatric surgery.

Farup P Sci Rep. 2024; 14(1):14844.

PMID: 38937532 PMC: 11211350. DOI: 10.1038/s41598-024-65952-y.


Prevalence and risk factors for secondary hyperparathyroidism (SHPT) in patients undergoing bariatric surgery.

Fischer L, Moreno-Garcia F, Tran R, Harmon A, Little C, Domingue G Surg Endosc. 2023; 37(10):8019-8028.

PMID: 37464065 DOI: 10.1007/s00464-023-10218-3.


Postoperative Osteoporosis in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomy.

Aaseth J, Alexander J Nutrients. 2023; 15(6).

PMID: 36986032 PMC: 10057453. DOI: 10.3390/nu15061302.


Long-Term Changes in Bone Density and Bone Metabolism After Gastric Bypass Surgery: a Retrospective Cohort Study.

Sperb L, Leotti V, Silveiro S, de Azevedo M, Viana L Obes Surg. 2023; 33(3):911-919.

PMID: 36609743 DOI: 10.1007/s11695-022-06448-4.